These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 11103240)
21. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094 [TBL] [Abstract][Full Text] [Related]
22. Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients. Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Schindl M; Kaider A; Leodolter S; Kainz C Anticancer Res; 2001; 21(1B):803-8. PubMed ID: 11299847 [TBL] [Abstract][Full Text] [Related]
23. A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer. Mayerhofer K; Bodner-Adler B; Bodner K; Saletu B; Schindl M; Kaider A; Hefler L; Leodolter S; Kainz C Anticancer Res; 2000; 20(5C):4051-5. PubMed ID: 11268500 [TBL] [Abstract][Full Text] [Related]
24. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362 [TBL] [Abstract][Full Text] [Related]
25. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994 [TBL] [Abstract][Full Text] [Related]
27. [Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)]. Yasuda M; Kimura E; Ochiai K; Tada S; Udagawa Y; Aoki D; Nozawa S; Kikuchi Y; Kita T; Nishida M; Tsunoda H Gan To Kagaku Ryoho; 2001 Apr; 28(4):493-8. PubMed ID: 11329783 [TBL] [Abstract][Full Text] [Related]
28. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC). Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237 [TBL] [Abstract][Full Text] [Related]
29. [The efficacy of Shakuyaku-Kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma]. Fujii K; Okamoto S; Saitoh K; Sasaki N; Takano M; Tanaka S; Kudoh K; Kita T; Tode T; Kikuchi Y Gan To Kagaku Ryoho; 2004 Oct; 31(10):1537-40. PubMed ID: 15508446 [TBL] [Abstract][Full Text] [Related]
30. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer. Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T Cancer Chemother Pharmacol; 2006 Jul; 58(1):86-90. PubMed ID: 16447041 [TBL] [Abstract][Full Text] [Related]
31. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. De Vos FY; Bos AM; Schaapveld M; de Swart CA; de Graaf H; van der Zee AG; Boezen HM; de Vries EG; Willemse PH Gynecol Oncol; 2005 Apr; 97(1):60-7. PubMed ID: 15790438 [TBL] [Abstract][Full Text] [Related]
32. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154 [TBL] [Abstract][Full Text] [Related]
33. Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel. Scalone S; Sorio R; Bortolussi R; Lombardi D; La Mura N; Veronesi A Acta Oncol; 2004; 43(2):209-11. PubMed ID: 15163172 [No Abstract] [Full Text] [Related]
34. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Watanabe Y; Nakai H; Ueda H; Hoshiai H Gynecol Oncol; 2005 Feb; 96(2):323-9. PubMed ID: 15661216 [TBL] [Abstract][Full Text] [Related]
35. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W; Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395 [TBL] [Abstract][Full Text] [Related]